No Data
No Data
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the "Company" or "NurExone"), a pioneering biopharmaceutical company,
NurExone Announces Expansion of ExoPTEN Patent Coverage With Notice of Allowance for Japanese Patent Application
TORONTO and HAIFA, Israel, June 11, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the "Company" or "NurExone"), a pioneering biopharmaceutical company
NurExone Announces Voting Results From 2024 Annual Meeting of Shareholders
TORONTO and HAIFA, Israel, June 04, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the "Company" or "NurExone"), a pioneering biopharmaceutical company
NurExone Biologic Inc.: Momentum and Market Growth
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations
TORONTO and HAIFA, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the "Company" or "NurExone"), a pioneering biopharmaceutical company,
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets With Approval of OTCQB Listing Application and DTC Eligibility
TORONTO and HAIFA, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV:NRX) (Germany: J90) (the "Company" or "NurExone"), a pioneering biopharmaceutical company is pleased to announce that its